CTI BioPharma (CTIC) Issues Quarterly Earnings Results, Misses Expectations By $0.06 EPS

CTI BioPharma (NASDAQ:CTIC) issued its earnings results on Thursday. The biopharmaceutical company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($0.06), MarketWatch Earnings reports. The business had revenue of $0.72 million for the quarter, compared to the consensus estimate of $0.60 million. CTI BioPharma had a negative net margin of 361.97% and a negative return on equity of 85.62%.

NASDAQ:CTIC traded up $0.03 during trading hours on Friday, reaching $1.80. The stock had a trading volume of 225,075 shares, compared to its average volume of 174,763. The company has a quick ratio of 4.28, a current ratio of 4.28 and a debt-to-equity ratio of 0.18. CTI BioPharma has a 52 week low of $1.66 and a 52 week high of $5.36.

A number of large investors have recently added to or reduced their stakes in the business. Northern Trust Corp increased its position in shares of CTI BioPharma by 434.3% during the 2nd quarter. Northern Trust Corp now owns 582,522 shares of the biopharmaceutical company’s stock valued at $2,900,000 after purchasing an additional 473,498 shares during the last quarter. Bank of New York Mellon Corp increased its position in shares of CTI BioPharma by 203.7% during the 2nd quarter. Bank of New York Mellon Corp now owns 150,671 shares of the biopharmaceutical company’s stock valued at $750,000 after purchasing an additional 101,055 shares during the last quarter. MetLife Investment Advisors LLC bought a new position in shares of CTI BioPharma during the 2nd quarter valued at approximately $137,000. Opaleye Management Inc. bought a new position in shares of CTI BioPharma during the 2nd quarter valued at approximately $803,000. Finally, Alambic Investment Management L.P. bought a new position in shares of CTI BioPharma during the 2nd quarter valued at approximately $617,000. 69.47% of the stock is currently owned by institutional investors and hedge funds.

Several analysts recently issued reports on the company. ValuEngine raised CTI BioPharma from a “sell” rating to a “hold” rating in a research note on Friday, August 3rd. Oppenheimer set a $4.00 target price on CTI BioPharma and gave the company a “buy” rating in a research note on Friday. Cann reissued a “buy” rating and set a $4.00 target price on shares of CTI BioPharma in a research note on Friday. BidaskClub downgraded CTI BioPharma from a “strong-buy” rating to a “buy” rating in a research note on Saturday, July 14th. Finally, Zacks Investment Research downgraded CTI BioPharma from a “hold” rating to a “sell” rating in a research note on Thursday, July 12th. Two analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average price target of $5.50.

About CTI BioPharma

CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States and internationally. It develops PIXUVRI, a novel aza-anthracenedione for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma; and pacritinib, an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R, which is in Phase III clinical trials for the treatment of adult patients with myelofibrosis.

Featured Story: How to Invest in Growth Stocks

Earnings History for CTI BioPharma (NASDAQ:CTIC)

Receive News & Ratings for CTI BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CTI BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply